When following therapy efficacy in melanoma, in addition to the classical circulating markers as LDH, S100 calcium-binding protein B (S100B), melanoma inhibitory activity (MIA) (Neagu et al., 2009), and, lately, ctDNA (Seremet et al., 2019), circulating miRNAs gained interest. Here, S100B is linked to melanoma.